RE:RE:RE:RE:Proof Is In The PuddingThanks winr88 for bringing that release back to light for us ... I took the liberty of highlighting key sentences showing the probability that all 6 Canadian sites have most likely been achieved with more patients enrolled and some treated.
winr88 wrote
Trials are just ramping up. From October 7 NR
With the addition of LHSC, the Company now has three sites open for patient enrollment and treatment; specifically, LHSC, University Health Network ("UHN") and McGill University Health Centre ("MUHC"). All sites are actively recruiting and screening new patients for enrollment in Study II. In addition, the Company has approximately six clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is specifically targeting strategic clinical sites throughout Canada and the US (subject to FDA Investigational New Drug ("IND") approval) that serve large populations or have the demographics to support patient enrollment and treatment. The Company anticipates that patient enrollment and treatment will escalate rapidly with the increased momentum as it launches additional clinical study sites, as UHN has now treated its second patient.
Shawn Shirazi, Ph.D., CEO - Drug Division, Theralase stated that, "I'm delighted that a high-quality organization such as LHSC has elected to join the Theralase team as the third Canadian study site that can enroll and treat patients with NMIBC, who are BCG-Unresponsive. We are working towards onboarding the rest of the Canadian study sites for Study II by the end of the year and hope to bring some US study sites on board before year end. The recent news from both patient five and six cancer-free status at 540 days from the Phase Ib study, which represents a 67% Complete Response ("CR") rate, supports the strong contention that the TLD-1433 Anti-Cancer Technology ("ACT") platform has the potential to be a viable treatment solution for CIS NMIBC BCG-Unresponsive patients, if the Company is able to duplicate the efficacy results observed in the Phase Ib clinical study."